Research and Markets: Viral Carcinogenesis Drug Pipeline Update 2013

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/3bqz9s/viral) has announced the addition of the "Viral Carcinogenesis Drug Pipeline Update 2013" report to their offering.

There is a strong association between viruses and the development of human malignancies. We now know that at least six human viruses, Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus (HCV), human papilloma virus (HPV), human T-cell lymphotropic virus (HTLV-1) and Kaposi's associated sarcoma virus (KSHV) contribute to 10-15% of the cancers worldwide. Via expression of many potent oncoproteins, these tumor viruses promote an aberrant cell-proliferation via modulating cellular cell-signaling pathways and escape from cellular defense system such as blocking apoptosis.

How May Drug Pipeline Update Be of Use?

- Show investors/board/management that you are right on top of drug development progress in your therapeutic area.

- Find competitors, collaborations partners, M&A candidates etc.

- Jump start competitive drug intelligence operations

- Excellent starting point for world wide benchmarking. Compare portfolio and therapy focus with your peers

Key Topics Covered:

Investigators

- Includes more than 174 principal companies plus their collaborators. There is direct access from inside the application to web pages of all principal companies.

Developmental

- This Drug Pipeline Update contains 211 viral carcinogenesis targeting drugs in development, which have a total of 718 developmental projects in cancer. In addition there are suspended and ceased drugs.

Indications

- Included viral carcinogenesis targeting drugs are also in development for 122 other indications, whereof 76 are different cancer indications.

Mutations

- All targets are cross-referenced with the Catalogue of Somatic Mutations in Cancer (COSMIC). It is designed to store and display somatic mutation information and related details and contains information relating to human cancers. To date 122 out of the 137 studied drug targets so far have been recorded with somatic mutations and the software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information.

Biological Structures

- The identity of available biological structures on 107 drug targets was retrieved from the RCSB Protein Databank for you to easily review the 2308 structures available today among drug targets.

For more information visit http://www.researchandmarkets.com/research/3bqz9s/viral

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology